TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of SHR-1703 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy Caucasian subjects, male and female, 18 to 55 years of age, inclusive;~2. Body weight ≥45 kg (Both male and female), body mass index (BMI) between ≥19.0 and ≤29.9 kg/m2, inclusive;~3. No clinically significant abnormalities in medical history, general physical examination, vital signs, laboratory tests (hematology, urinalysis, blood chemistry and coagulation function) and ECG at the investigator's discretion during screening and baseline.~4. Men and women of childbearing potential (WOCBP) must agree to take effective contraceptive methods and have no plan to have a child from signing the consent form to 30-days after last scheduled follow-up visit.~Exclusion Criteria:~1. Known history or suspected of being allergic to the study drug.~2. Positive hepatitis B virus (HBsAg), hepatitis C virus (HCV-Ab), human immunodeficiency virus (HIV-Ab) at screening.~3. Participation in clinical trials of other investigational drugs or medical devices within 3 months prior to screening or within 5 half-lives of any drugs during screening visit, or in the follow-up period of a clinical study whichever is longer~4. Use of any medicine within 4-weeks prior to the IP administration~5. Blood donation or loss of more than 400 mL of blood within 1 month of screening; or received blood transfusion within 2 months before screening.~6. Live (attenuated) vaccination within 1 month before screening or plan to be vaccinated~7. Severe injuries or major surgeries within 6 months before screening or plan to do surgeries during the trial~8. Patients with known or suspected parasitic infection within 6 months before screening~9. Either ALT, AST, ALP, GGT or total bilirubin level exceeds upper limit of normal range (ULN) at screening or baseline visits (confirmed by a single repeat, as per investigator's judgment)~10. More than 5 cigarettes daily (or products with equivalent amount of nicotine) for 3 months prior to screening.~11. History of alcohol abuse within 3 months prior to the IP administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- SHR-1703 Dose Level 1 (Type: EXPERIMENTAL): Dose level 1 SHR-1703
- SHR-1703 Dose Level 2 (Type: EXPERIMENTAL): Dose level 2 SHR-1703
- SHR-1703 Dose Level 3 (Type: EXPERIMENTAL): Dose level 3 SHR-1703
- SHR-1703 Dose Level 4 (optional) (Type: EXPERIMENTAL): Dose level 4 SHR-1703 Additional dose escalations, as determined by the SMC depend on PK and safety data review

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of non-small cell lung cancer~  * Locally advanced or metastatic disease~* Requires definitive thoracic and mediastinal radiotherapy with concurrent chemotherapy~  * Total planned radiation dose to gross disease 60-80 Gy~PATIENT CHARACTERISTICS:~* No diagnosis of disease of the gastrointestinal (GI) system, liver, or kidneys that could result in altered metabolism or excretion of the study medication (e.g., history of major GI tract surgery, gastrectomy, gastrostomy, or bowel resection)~* No history of chronic GI disorders (e.g., ulcerative colitis, regional enteritis, or GI bleeding)~* No known hypersensitivity to flaxseed or any of its metabolites or to wheat products~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* See Patient Characteristics~* More than 14 days since prior and no concurrent investigational drugs~* More than 14 days since prior and no concurrent amifostine or Mucomyst (N-acetylcysteine)~* No prior thoracic radiotherapy~* No prior or other concurrent flaxseed, flax-containing products, soybeans, or soy-containing products~* No other concurrent dietary supplements, such as herbals or botanicals~  * Vitamins or multivitamins, including calcium and vitamin D, are allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients consume flaxseed muffins once or twice daily beginning on the first day of radiotherapy and continuing for up to 9-10 weeks.
- Arm II (Type: PLACEBO_COMPARATOR): Patients consume placebo muffins once or twice daily beginning on the first day of radiotherapy and continuing for up to 9-10 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys™ Spray.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 18 years of age.~* Subjects who are experiencing 1-4 episodes of break through pain per day in spite of optimized background analgesia and who have taken at least 60 mg/day of morphine (or equivalent analgesic) for at least 7 days.~* Who are currently using Actiq® for their breakthrough pain and are being discontinued due to lack of efficacy, side effects, patient dissatisfaction or prescriber dissatisfaction with treatment.~* Are able to follow and complete all necessary study procedures.~* Are willing and able to give written informed consent before participating in the study.~* Enrolled in the class wide REMS as verified by the study personnel.~Exclusion Criteria:~* Subjects who are not opioid tolerant.~* Using a rapid onset opioid other than Actiq® to manage their breakthrough pain.~* Have physical abnormalities of the floor of the mouth that could affect absorption as determined by investigator.~* Are subjects with uncontrolled or rapidly escalating pain.~* Are subjects with a history of alcohol or substance abuse within the last 3 years.~* Have a clinically significant medical history (past or present) of any disease that would compromise the study or the well-being of the subject.~* Are subjects who have participated in another clinical trial with an analgesic within the last month.~* Are female subjects with a positive pregnancy test or who are currently lactating.~* Are subjects who are taking medications that are known inhibitors of the CYP3A4 isozyme, such as ketoconazole.~* Are subjects who have taken a monoamine inhibitor within 14 days before a dose of study medication.~* Opioid being used for chronic migraine or acute pain.~* Are subjects who are unsuitable for inclusion for any other reason, in the opinion of the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subsys (Type: None): Cancer patients experiencing breakthrough pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vacuum Assisted Closure for Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients that have undergone cesarean section for delivery; have a BMI greater or equal to 35. All cases of cesarean section including primary and repeat, scheduled and urgent.~Exclusion Criteria:~* Patients who deliver vaginally; age less than 18 years old; silver allergy; non-English speaking

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Vacuum-assisted closure (VAC) (Type: EXPERIMENTAL): Prevena (VAC) device
- Standard sterile dressing (Type: ACTIVE_COMPARATOR): Standard sterile dressing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: BreathID Multi-center HCV Liver Breath Test Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~i. Patients with a confirmed diagnosis of Chronic HCV only : ii. Patients for whom a liver biopsy has been performed within the last 90 days or who will undergo a liver biopsy within the time frame of the study.~Exclusion Criteria:~i. Severe congestive heart failure. ii. Severe pulmonary hypertension. iii.Chronic renal insufficiency defined by a serum creatinine above the limits of normal. iv. Uncontrolled diabetes mellitus (need definition).v.Any autoimmune disorder, which is currently being treated with prednisone or any other immune suppressive medication. vi.Proven or suspected hepatocellular carcinoma. vii. Previous surgical bypass surgery for morbid obesity viii.Extensive small bowel resection. ix.Patients currently receiving total parenteral nutrition x.Recipients of any organ transplant. xi.Other co-existent liver disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MBT (Type: EXPERIMENTAL): C13 methacetin dissolved in water to be ingested after breath baseline collected. Metabolism to measured in real time.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. IgA nephropathy confirmed by pathological biopsy;~2. Male or female aged ≥ 18 years old;~3. Average 24-hour urine total protein ≥ 0.75 g/24 h~4. Estimated GFR (using the CKD-EPI formula) \> 30 mL/min per 1.73 m\^2;~5. Stabilized AEI/ARB medications, diuretics, or other antihypertensive therapy.~Exclusion Criteria:~1. Patients with clinically significant abnormal laboratory tests at screening;~2. Evidence of rapid eGFR decrease \> 15 ml/min during screening;~3. Renal or other organ transplantation prior to, or expected during, the study;~4. Patients with secondary IgA nephropathy;~5. Patients with nephrotic syndrome, crescentic nephritis minimal change nephropathy with IgA deposition, or other pathological or clinical types of renal diseases that may confound the study data interpretation;~6. Patients with history of any severe unstable cardiovascular and cerebrovascular events within 12 weeks prior to screening;~7. Immunocompromised individuals.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telitacicept 160mg (Type: EXPERIMENTAL): Telitacicept 160mg subcutaneous injection once weekly, and a total of 24 doses
- Telitacicept 240mg (Type: EXPERIMENTAL): Telitacicept 240mg subcutaneous injection once weekly, and a total of 24 doses
- Placebo (Type: PLACEBO_COMPARATOR): Placebo subcutaneous injection once weekly, and a total of 24 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: SP16 as a Therapeutic for COVID-19 Induced ARDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~To be considered eligible to participate in this study, the subject must meet all of the Inclusion criteria listed below:~* Hospitalized patients age ≥ 18 with diagnosis of SARS-CoV-2-infection based on positive~* PCR test result and can provide informed consent~* Diagnosed with pneumonia due to SARS-CoV-2~* Respiratory rate ≥ 25/minute and SpO2 ≤ 93%~* Review of Chest radiograph, chest computed tomography (CT) scan, or chest ultrasound consistent with bilateral infiltrates.~* Horowitz index (partial pressure of oxygen/fraction of inspired oxygen \[PaO2/FiO2\]) ≤ 300. If a subject does not have an arterial line in place, a SpO2/FiO2 ≤ 315 may be used.~Exclusion Criteria:~To be eligible for entry into the study, the subject must not meet any of the exclusion criteria listed below:~* Age \< 18~* Pregnant or lactating women~* History of heart failure~* Clinically significant cardiac dysrhythmia, as determined by investigator~* History renal impairment~* Presence of any of the following abnormal laboratory values at screening: absolute neutrophil count (ANC) less than 2000 mm3, aspartate aminotransferase

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort dose 1 of SP16 (Type: EXPERIMENTAL): Patients in cohort 1 (low dose SP16) will receive a single dose of SP16 (0.1 mg/kg or 6 mg) by subcutaneous injection
- Cohort dose 2 of SP16 (Type: EXPERIMENTAL): Patients in cohort 2 (high dose SP16) will receive a single dose of SP16 (0.2 mg/kg or 12 mg) by subcutaneous injection
- Placebo (Type: PLACEBO_COMPARATOR): Patients in placebo arm will receive sterile water by subcutaneous injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Ephedrine vs Phenylephrine - ECG Changes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to give written informed consent~2. \>37/40 weeks gestation~3. Singleton pregnancy~4. Elective caesarean section under spinal anaesthesia~5. In good general health (American Society of Anesthesiology Category 1 or 2, fit and well or with mild systemic disease that has no impact on physical activity )~Exclusion Criteria:~1. Circulatory disease (eg pre-existing hypertension)~2. Cardiac disease/medications (e.g. angina, cardiomyopathy, B Blocker medication)~3. Pregnancy related disease (eg pre-eclampsia)~4. Diabetes pre-existing the pregnancy~5. Hyperthyroidism~6. Renal Disease~7. Closed-angle glaucoma~8. Patients on monoamine oxidase inhibitors~9. In active labour~10. Emergency caesarean section~11. Fetal abnormalities~12. Contraindications to spinal anaesthesia~13. Height \>6 feet/180cm / Height \<5 feet/150cm~14. Body mass index (BMI) \<19 or \>35

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- phenylephrine infusion (Type: ACTIVE_COMPARATOR): None
- Ephedrine infusion (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Angiotensin-converting Enzyme Inhibitors and Early Sickle Cell Renal Disease in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sickle cell disease (SS, SC, Sb thalassemia, SD Punjab)~* Affiliation to French Health benefits~* Signed informed consent~* Albuminemia / Creatinemia \>= 3 mg / mmol (on 2 samples)~Exclusion Criteria:~* Albuminemia / Creatinemia \> 100 mg / mmol~* Hypersensibility to enalapril~* Angio-oedemas due to a previous treatment by ACE~* idiopathic or hereditary angio-oedemas~* cerebral echo-doppler~* treatment by lithium digoxine~* treatment by other ACE~* congenital galactosemia~* Pregnancy

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: PLACEBO_COMPARATOR): None
- 1 (Type: EXPERIMENTAL): Enalapril

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of MRI and SPECT Fusion Software to Localize Parathyroid Adenomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are 18 years and over~* subjects who have had a failed parathyroidectomy and now presents with persistent hyperparathyroidism or recurrent hyperparathyroidism~* 6 control patients with parathyroid adenomas who have not yet had surgery will be selected to test the efficacy of the software.~Exclusion Criteria:~* Potential female subjects who are pregnant~* Any potential subject who has an implanted metallic device, stent or staples~* any subject weighing 300lb

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): subjects who are diagnosed with parathyroid adenomas. There will be 6 subjects who have not had surgery and 25 subjects who have had surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination: Feasibility Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for the Parent-Adolescent Dyad:~* Parents: Undecided about the HPV vaccine~* Adolescent child: 11-17 years old and has not begun the HPV vaccine series.~Exclusion Criteria:~* Parents: Having impairing hearing or speech~* Adolescents: pregnant at the time of the clinic visit~* Dyad: participated in Phase 1 and 2 of the study

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Self-persuasion group (Type: EXPERIMENTAL): HPV information plus self-persuasion intervention in a tablet-based application (Project Voice)
- Information only group (Type: ACTIVE_COMPARATOR): HPV information only in a tablet-based application (HPV Informational Video)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Spinal Cord Stimulation in Heart Failure Patients With Depressed Left Ventricular Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with chronic heart failure II-III class (NYHA);~2. Age 18-70 years;~3. Left ventricle ejection fraction ≤35%;~4. Optimal heart failure management according to the guidelines;~5. Signed informed consent~Exclusion Criteria:~1. Heart transplant list;~2. Acute conditions, including systemic infection;~3. Reversible cause of heart failure (thyroid gland diseases, alcoholic intoxication etc);~4. Planned elective heart surgery or intervention;~5. Recent (3 months) myocardial infarction, coronary intervention;~6. Heart failure decompensation;~7. Implanted cardiac resynchronization device \< 6 months ago;~8. Contraindications for lumbal puncture or placement of a spinal cord pacing electrode;~9. Permanent atrial fibrillation;~10. Stroke or TIA \< 6 months ago;~11. Pulmonary thromboembolist \< 3 months ago;~12. Hypertrophic cardiomyopathy with obstruction;~13. Angina III-IV class, or congestive heart failure IV class;~14. Participation in any other clinical trial;~15. Women of childbearing possibility without appropriate contraception, pregnant, or breastfeeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Spinal cord stimulation on top of standard treatment
- Control (Type: NO_INTERVENTION): Standard treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of a Non-Invasive Central Venous Pressure Monitoring System in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 12 months of age to 10.9 years of age~* Scheduled to undergo a cardiac surgery with central venous pressure catheter monitoring at Boston Children's Hospital~Exclusion Criteria:~* undergo a procedure that does not require a central venous pressure catheter as part of routine monitoring~* Have a known venous occlusion or any other reason the central venous pressure may be unreliable~* Allergy to medical grade adhesives or have any pre-existing skin irritation/eczema at the sensor site~* Emergently scheduled procedures

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Non-invasive monitoring (Type: None): In addition to standard monitoring, the Mespere VENUS 200CVP system will be used to record central venous pressures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility